SOPHiA GENETICS

Europe, you are on 🔥! 🚀 We are thrilled to wrap up another exciting week full of activities all across the EMEA region! 🌍 From Paris to Basel and Zurich, our team has been thrilled to connect with our international community of pathologists, oncologists and hematology experts to discuss our latest innovations and shared mission on democratizing data-driven medicine across borders. Moments from our highlight congresses this week: 🇨🇭 90th Annual Congress of the Swiss Society of Pathology (Zurich) Axel de Tonnac Veronika Schuler Marinela Lekka, MBA 🇫🇷 Carrefour Pathologie (Paris) Mathieu CARRE Narimène Asbelaoui 🇨🇭Swiss Oncology & Hematology Congress 2025 (Basel) Marinela Lekka, MBA Gwendal Le Martelot Jan Henrik BIDART 🙏Thanks to everyone who stopped by our booths and met our team in person. Your curiosity and energy keeps pushing us forward! Next station.... 🇩🇪 Bonn and the 15th Autumn Meeting for Molecular Pathology! Germany, see you next week! #SOHC #SGPath #CarrefourPathologie #oncology #pathology #datadrivenmedicine

At SOPHiA GENETICS, sustainability is part of who we are. 🌱 On 7 November 2025, our colleagues joined TEDx Lausanne Countdown 2025, an event dedicated to “Rethinking the System for Climate Action.” Many of the ideas shared on stage aligned with the approach we take as a company: • building efficient, scalable digital solutions that support healthcare systems worldwide, • promoting streamlined, resource-conscious workflows, and • staying aware of the environmental impact of our decisions as we grow. Being present at TEDx Lausanne allowed us to stay close to the climate conversation and bring new perspectives back into our teams — helping us strengthen both our environmental responsibility and our positive impact on people and health systems. One step closer to a future where healthcare is more precise, more accessible, and more sustainable. #ClimateAction #Sustainability #DataDrivenMedicine #AIinHealthcare #PrecisionOncology #FutureOfHealthcare #TEDxLausanne

🧬 Companion Diagnostics (CDx) have become essential tools to realize the promise of precision oncology. But are current approaches to CDx keeping pace with the speed, efficiency, and scalability that pharma companies need? 🚀 At SOPHiA GENETICS’, we are rethinking the future of CDx. Our hybrid testing, powered by strategic partnerships, accelerates innovation, drives meaningful clinical and commercial impact, and strengthens health equity. 👉🏼 Read our article: https://loom.ly/Kedt2Yo #DataDrivenMedicine #PrecisionMedicine #Genomics #HealthEquity #CDx

🔬 From Complexity to Clarity: Streamlining Variant Investigation with Alamut™ Visual Plus Join our upcoming webinar for a deep dive into the workflows and capabilities that support accurate and confident variant interpretation. We’ll showcase how intuitive visualization, integrated annotations, splicing predictions, and ACMG guidance come together to standardize and accelerate variant review. Plus — see the software in action during a live demonstration. 📅 Dec 3, 2025 10AM EST | 4PM CET 🔗 Register now: https://loom.ly/9FRgW_Y #Genomics #Bioinformatics #VariantInterpretation #ClinicalGenomics #NGS #Alamut

🇨🇴 We’re thrilled to welcome Seguros SURA Colombia to the SOPHiA GENETICS community as they adopt MSK-ACCESS® powered by SOPHiA DDM™ to advance their precision oncology research initiatives. As one of Latin America’s leading healthcare organizations, Seguros SURA Colombia is recognized for its commitment to driving innovation and research that strengthens the healthcare ecosystem. By implementing this cutting-edge liquid biopsy solution for research purposes, SURA is empowering its teams to generate insights that will help advance precision medicine initiatives in Colombia and across the region. “We are excited to integrate MSK-ACCESS® powered by SOPHiA DDM™ into our Omics Sciences Center. This platform will enable us to deepen our understanding of cancer biology and contribute to the growth of precision medicine in Colombia,” said Carlos Andres Agudelo, Manager of the Biosciences Center, Seguros SURA Colombia. At SOPHiA GENETICS, our mission is to democratize data-driven medicine worldwide by giving healthcare and research institutions access to powerful, AI-enabled analytics that transform complex data into meaningful insights. We’re proud to partner with Seguros SURA Colombia as they take this important step toward advancing precision oncology research across the region. Here’s to expanding access to innovation and accelerating research for better outcomes. 🧬 Learn more about MSK-ACCESS® powered with SOPHiA DDM™: https://loom.ly/zQYA7bw 🌎 #PrecisionOncology #ClinicalGenomics #LiquidBiopsy #MSKACCESS #SOPHiAGENETICS #HealthcareInnovation #LatinAmerica

#AMPath2025 was full of energy from start to finish! Thank you to everyone who attended our Corporate Workshops, joined our Blood Cancers Showcase, stopped by our posters, took part in our booth conversations and activities, and kept the ideas flowing in every corner of the conference center 💫 📹 Check out our recap video! Hear from Philippe Menu (EVP, CMO & CPO), Zhenyu Xu (EVP, CSO), Ross Muken (President), and John Carey, MBA (Managing Director, North America) as they highlight the best moments from the week and their excitement for what’s ahead! Association for Molecular Pathology (AMP) #Pathology #Multimodal #AssociationforMolecularPathology

We’re still buzzing from our Blood Cancers Showcase! The turnout was amazing, and we’re excited to keep building on the insights and connections. Our fantastic trio of speakers showed how NGS workflows are uniquely suited to address the complexity of the blood cancer journey, facilitating discovery and monitoring – while helping teams optimize resources and effort. We learned from: 💫 Dr. Gayatry Mohapatra (UIC) how comprehensive myeloid malignancy solutions enable labs to go broader and deeper in a single run, powering more confident insights without adding extra hands-on time 💫 Dr. Melania Abreu (Genos Médica) how, for common conditions like CLL, high-throughput approaches can help streamline diagnosis and reduce costs, enabling more efficient detection of early-stage, high-risk cases 💫 Dr. Juan Gomez-Gelvez (Henry Ford) how NGS-based MRD applications offer high sensitivity and broad applicability in AML, but standardization and harmonization are still critical for their widespread clinical implementation Thank you to everyone who joined us and made the showcase such a highlight of our time at #AMPath2025! #Pathology #Multimodal Association for Molecular Pathology (AMP)

Proud to continue my Research Spotlight series with a recent study published in Nature Communications, where the SOPHiA DDM™ Platform supported monitoring of Ataluren treatment in patients with Shwachman-Diamond syndrome (SDS). SDS is a rare inherited ribosomopathy that disrupts both hematopoiesis and pancreatic function. Ataluren, a drug repurposed from Duchenne muscular dystrophy, was tested under a compassionate use program in three patients (aged 13–20) over 12 months. Highlights from the study: · Protein and cellular restoration: Western blot analyses showed increased SBDS protein levels in bone marrow and peripheral blood mononuclear cells following Ataluren treatment. · Bone marrow improvement: Histological examination revealed increased cellularity (up to 30-40% post-treatment versus 5-20% pre-treatment) and enhanced maturation of myeloid progenitors. Colony assays confirmed increased myeloid colony formation. · Hematologic recovery: Absolute neutrophil counts normalized in two patients and platelet counts increased in all three, with modest but favorable changes in erythroid lineages. · Pancreatic function: Digestive enzyme levels levels rose significantly, indicating improved pancreatic activity. · Reduced cellular stress: Treatment led to decreased phosphorylation of mTOR (S2448) in leukocytes, lymphocytes, and monocytes, reflecting alleviated ribosomal stress. · Immunophenotypic changes: Memory B cell populations normalized, suggestive of immune recovery. · Safety: Treatment was well tolerated with no serious side effects or concerning changes in TP53 gene mutations. Genomic monitoring of TP53 variants was performed using next-generation sequencing analyzed via the SOPHiA DDM™ Platform, ensuring highly sensitive detection (down to 2%) and robust genetic surveillance during treatment. This research shows how repurposing read-through drugs combined with precision genomics can move us from symptomatic care to molecular correction, bringing hope to families affected by rare diseases. Congratulations to the authors and institutions advancing this vital work. 

✈️ We’re excited to be in Basel this week for the 8th Swiss Oncology & Hematology Congress! 🇨🇭 Join us at Booth 45 to explore our latest innovations in hemato-oncology and beyond, from advanced analytics to cutting-edge workflows designed to empower clinicians with deeper, more actionable insights. 💡Stop by to connect with our team, discover what’s new, and see how we’re helping drive the future of data-driven precision medicine. We look forward to meeting you in Basel! #SOHC #SOHC2025 #hematooncology

Super nice to see the publication this week in NPJ Artificial Intelligence of our latest perspectives on the ongoing AI multimodal revolution in oncology, alongside our wonderful partners at AstraZeneca, Memorial Sloan Kettering Cancer Center and NVIDIA. The paper is a collaborative review of the current status and direction of travel of applying AI to multimodal data stacks across the oncology care continuum. Excited to specifically see our joint work on the TRIDENT and ABACO initiatives with AstraZeneca and Memorial Sloan Kettering Cancer Center called out! Warmly recommend the read! Agree or disagree with the perspectives contained in the paper? Please comment below! Congrats to our colleagues David Dellamonica, David Ruau, Ben Griffiths, Greg Rossi, Bob Li, Pedram Razavi, Thomas Di Maio, Tristan Gonzalez, Amanda Remorino, Jorge Reis-Filho, Thorsten Gutjahr, Adrien Moucquot, Tom Diethe, S. Hassan N., Pablo Azcue MD, MEng, PhD and our very own Ross Muken! https://lnkd.in/ePgsXA22